USD
+$0.00
(+0.00%
)At Close (As of Sep 26, 2025)
$19.56M
Market Cap
-
P/E Ratio
-4.87
EPS
$13.50
52 Week High
$0.65
52 Week Low
HEALTHCARE
Sector
Field | Value (USD) |
---|---|
Gross Profit | -$210K |
Total Revenue | $0 |
Cost Of Revenue | $210K |
Costof Goods And Services Sold | $210K |
Operating Income | -$42M |
Selling General And Administrative | $18M |
Research And Development | $12M |
Operating Expenses | $42M |
Investment Income Net | - |
Net Interest Income | $758K |
Interest Income | $758K |
Interest Expense | - |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $210K |
Income Before Tax | -$39M |
Income Tax Expense | $576K |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$39M |
Comprehensive Income Net Of Tax | - |
Ebit | -$39M |
Ebitda | -$39M |
Net Income | -$39M |
Field | Value (USD) |
---|---|
Total Assets | $117M |
Total Current Assets | $14M |
Cash And Cash Equivalents At Carrying Value | $3.3M |
Cash And Short Term Investments | $3.3M |
Inventory | $8.3M |
Current Net Receivables | - |
Total Non Current Assets | $102M |
Property Plant Equipment | - |
Accumulated Depreciation Amortization Ppe | - |
Intangible Assets | $93M |
Intangible Assets Excluding Goodwill | $93M |
Goodwill | $9.3M |
Investments | - |
Long Term Investments | - |
Short Term Investments | - |
Other Current Assets | $2.7M |
Other Non Current Assets | - |
Total Liabilities | $43M |
Total Current Liabilities | $36M |
Current Accounts Payable | $4.9M |
Deferred Revenue | - |
Current Debt | - |
Short Term Debt | $242K |
Total Non Current Liabilities | $6.7M |
Capital Lease Obligations | $263K |
Long Term Debt | - |
Current Long Term Debt | - |
Long Term Debt Noncurrent | - |
Short Long Term Debt Total | $263K |
Other Current Liabilities | $31M |
Other Non Current Liabilities | - |
Total Shareholder Equity | $70M |
Treasury Stock | - |
Retained Earnings | -$201M |
Common Stock | $7.2K |
Common Stock Shares Outstanding | $12M |
Field | Value (USD) |
---|---|
Operating Cashflow | -$28M |
Payments For Operating Activities | - |
Proceeds From Operating Activities | - |
Change In Operating Liabilities | - |
Change In Operating Assets | - |
Depreciation Depletion And Amortization | $210K |
Capital Expenditures | $0 |
Change In Receivables | - |
Change In Inventory | -$2.1M |
Profit Loss | - |
Cashflow From Investment | -$5M |
Cashflow From Financing | $10M |
Proceeds From Repayments Of Short Term Debt | - |
Payments For Repurchase Of Common Stock | - |
Payments For Repurchase Of Equity | - |
Payments For Repurchase Of Preferred Stock | - |
Dividend Payout | - |
Dividend Payout Common Stock | - |
Dividend Payout Preferred Stock | - |
Proceeds From Issuance Of Common Stock | - |
Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
Proceeds From Issuance Of Preferred Stock | - |
Proceeds From Repurchase Of Equity | - |
Proceeds From Sale Of Treasury Stock | - |
Change In Cash And Cash Equivalents | - |
Change In Exchange Rate | - |
Net Income | -$39M |
Field | Value (USD) |
---|---|
Gross Profit | -$210K |
Total Revenue | $0 |
Cost Of Revenue | $210K |
Costof Goods And Services Sold | $210K |
Operating Income | -$42M |
Selling General And Administrative | $18M |
Research And Development | $12M |
Operating Expenses | $42M |
Investment Income Net | - |
Net Interest Income | $758K |
Interest Income | $758K |
Interest Expense | - |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $210K |
Income Before Tax | -$39M |
Income Tax Expense | $576K |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$39M |
Comprehensive Income Net Of Tax | - |
Ebit | -$39M |
Ebitda | -$39M |
Net Income | -$39M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Citius Pharmaceuticals, Inc. (CTXR) is a specialized pharmaceutical company focused on developing and commercializing innovative critical care products. Based in Cranford, New Jersey, Citius is dedicated to addressing unmet medical needs through a robust pipeline, which includes therapies for serious conditions in hospital settings. By leveraging cutting-edge technology and strategic collaborations, Citius aims to enhance patient outcomes and establish itself as a leader in the critical care market.